The supplementary materials for the study "Targeting conserved TIM3+ VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy" include figures and tables that support the main findings. Figure S1 shows the expression of HAVCR2 and VSIR in immune cells from immuno-resistant human tumors. Figure S2 presents a pan-cancer immune landscape classification. Figure S3 illustrates TIM3+ VISTA+ TAMs in an immuno-resistant murine tumor. Figure S4 demonstrates the specific phenotype of TIM3+ VISTA+ TAMs in mouse and human tumors. Figure S5 shows the therapeutic blockade of TIM3+ VISTA+ TAMs in vivo. Figure S6 details immunogenic cell death induced by chemotherapy in LLC and MC38 cancer cells. Figure S7 shows that TIM3 and VISTA are pro-efferocytic. Figure S8 indicates that blocking TIM3 or VISTA increases MHCII+ macrophages. Figure S9 shows that suppressed LLC tumors do not enrich anti-tumor T cell subsets. Figure S10 shows that suppressed LLC tumors do not enrich DC subsets. Figure S11 discusses tumor-associated macrophages. Figure S12 presents the depletion of macrophages and CD8+ T cells. Figure S13 details TAM-specific genetic ablation of TIM3 and VISTA. Figure S14 explores how low antigenicity drives IL4-driven accumulation of TIM3+ VISTA+ TAMs. Figure S15 provides immunophenotyping of different melanoma tumor models. The supplementary materials also include gating strategies, western blots, and tables summarizing the data. These materials provide detailed analysis of the immune landscape, TAM characteristics, and the effects of targeting TIM3 and VISTA in cancer therapy.The supplementary materials for the study "Targeting conserved TIM3+ VISTA+ tumor-associated macrophages overcomes resistance to cancer immunotherapy" include figures and tables that support the main findings. Figure S1 shows the expression of HAVCR2 and VSIR in immune cells from immuno-resistant human tumors. Figure S2 presents a pan-cancer immune landscape classification. Figure S3 illustrates TIM3+ VISTA+ TAMs in an immuno-resistant murine tumor. Figure S4 demonstrates the specific phenotype of TIM3+ VISTA+ TAMs in mouse and human tumors. Figure S5 shows the therapeutic blockade of TIM3+ VISTA+ TAMs in vivo. Figure S6 details immunogenic cell death induced by chemotherapy in LLC and MC38 cancer cells. Figure S7 shows that TIM3 and VISTA are pro-efferocytic. Figure S8 indicates that blocking TIM3 or VISTA increases MHCII+ macrophages. Figure S9 shows that suppressed LLC tumors do not enrich anti-tumor T cell subsets. Figure S10 shows that suppressed LLC tumors do not enrich DC subsets. Figure S11 discusses tumor-associated macrophages. Figure S12 presents the depletion of macrophages and CD8+ T cells. Figure S13 details TAM-specific genetic ablation of TIM3 and VISTA. Figure S14 explores how low antigenicity drives IL4-driven accumulation of TIM3+ VISTA+ TAMs. Figure S15 provides immunophenotyping of different melanoma tumor models. The supplementary materials also include gating strategies, western blots, and tables summarizing the data. These materials provide detailed analysis of the immune landscape, TAM characteristics, and the effects of targeting TIM3 and VISTA in cancer therapy.